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Seven new compounds have been synthetized in satis-
factory yields (51–78 %) through the treatment of meso-
ionic 1,3-thiazolium-5-thiolate (4a–d) and 1,3,4-thiadia-
zolium-5-thiolate (10a,b) with chloroacetic acid or methyl
iodide: 1,3,4-thiadiazolium-5-methylthio- (11) and 5-thio-
acetate (12). The structure of the title compounds was elu-
cidated by elemental analysis, IR, 1H and 13C NMR spec-
troscopy. The newly synthesized compounds 5a, 6a, 11 and
12 were evaluated for their ex vivo spasmolytic potential
on four isolated smooth muscles (rat aorta and uterus,
guinea pig ileum and trachea) and compared with scopol-
amine. Some of the compounds exhibited potent spas-
molytic activity equal to or stronger than scopolamine.
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For decades, mesoionic compounds have attracted the interest of researchers around
the world, either due to their peculiar chemical characteristics or the large number of
biological activities provided by this class of substances (1). In 1996, mesoionic compo-
unds were defined as planar five-membered heterocyclic betaines with, at least, one
side-chain whose a-atom is also in the ring plane with dipole moments of the order of 5
D. Electrons are delocalized over two regions separated by what are essentially single
bonds. One region which includes the a-atom of the side-chain is associated with the
HOMO and negative p-charge whereas the other is associated with the LUMO and po-
sitive p-charge (2).
Due to their structural characteristics and properties, mesoionic compounds have
attracted attention of many researchers in two major areas: photonics and non-linear op-
tical studies (3–6) and medicinal chemistry. In the latter area, the literature describes a
wide range of biological activities associated with this class of compounds, including,
among others, analgesic, anti-inflammatory, anticancer, antimicrobial, antihypertensive,
antiplatelet, thrombolytic, trypanocidal and leishmanicidal activities (7–13).
Continuing our studies on physical, chemical and biological properties of mesoionic
derivatives, we report here the synthesis and structural elucidation of methylthio- and
thioacetate- derivatives of the mesoionic systems 1,3-thiazolium-5-thiolate and 1,3,4-
thiadiazolium-5-thiolate along with their spasmolytic effects on isolated smooth muscles.
EXPERIMENTAL
Reagents and general procedures
All reagents and solvents used were commercially obtained (Sigma-Aldrich, Brazil)
and used without further purification. The course of reactions was monitored by TLC on
0.25-mm silica gel plates (60F254, Merck, Germany). Hexane/chloroform mixtures were
used as eluents. The final products were purified by column chromatography using ne-
utral alumina (Merck) and the same eluents as used for TLC. The compounds were puri-
fied by recrystallization. Melting points were measured on a platinum plate in a Koffler
apparatus coupled with a Carl-Zeiss microscope and are uncorrected. Elemental analys-
es were performed using an EA 1110 CHNS-O elemental analyzer (CE instruments, UK).
The results were found to be in accord (± 0.4 %) with the calculated values. IR spectra
were obtained on a Bomen-Michelson IFS 66 spectrometer (Bruker, USA) using KBr discs.
NMR spectra were recorded on a VARIAN spectrometer UNITY PLUS (Varian, USA)
with a 5-mm probe with a channel magnetic field gradient operating at 200 MHz for 1H
NMR and 50 MHz for 13C NMR, using tetramethylsilane as internal standard. Chemical
shifts are reported in ppm (d), and coupling constants (J) are reported in Hz. Spectral,
physical and analytical data of all newly synthesized compounds are listed in Tables I
and II.
General synthesis procedure
5-Methylthio (5a–c, 11) and 5-thioacetate (6a,b, 12) derivatives. – An equimolar mixture of
mesoionic compounds [(4a–d or 10a,b, synthesized according to previous procedures (14,
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15)] suspended in absolute ethanol and methyl iodide (for methylthio derivatives 5a–c, 11)
or chloroacetic acid (for thioacetate derivatives 6a,b, 12) was stirred under room tempe-
rature until the observed color change to pale yellow (around 2 hours). The solvent was
evaporated under reduced pressure and the solid residue obtained was recrystallized from
ethanol/diethyl ether 1:1, affording pure crystals of 2-(4-chlorophenyl)-3-N-methyl-4-
-phenyl-1,3-thiazolium-5-methylthio iodide (5a), 2-(4-chlorophenyl)-3-N-methyl-4-(isopropyl-
-phenyl)-1,3-thiazolium-5-methylthio iodide (5b), 2-(4-chlorophenyl)-3-N-methyl-4-(meto-
xyphenyl)-1,3-thiazolium-5-methylthio iodide (5c), 2-(4-chlorophenyl)-3-methyl-4-phenyl-
-1,3-thiazolium-5-thioacetate (6a), 2-(4-trifluoromethyl-phenyl)-3-N-methyl-4-(isopropyl-
-phenyl)-1,3-thiazolium-5-thioacetate (6b), 2-(4-chlorophenyl)-3-phenyl-1,3,4-thiadiazolium-
-5-methylthio iodide (11) and 2,3-diphenyl-1,3,4-thiadiazolium-5-thioacetate (12) (Schemes
1 and 2).
Animals
Adult guinea-pigs of both sexes (Cavia porcellus, 300–500 g), male and female Wistar
rats (Rattus norvegicus, 200–350 g), obtained from the Thomas George Biotery, Labora-
tório de Tecnologia Farmacêutica of the Federal University of Paraiba, were used. The
animals were submitted to the following conditions: 12 h light/12 h dark cycle (lights
on: 06:00–18:00 h), filtered conditioned air, 23 ± 2 °C, 50–70 % humidity, sterilized bed;
Purina® pellets (Nestle, Brazil) and drinking sterilized water ad libitum were used. All
sets of experiments were carried out in the period from 7:00 to 14:00 h.
Animal handling and procedures were performed according to international guide-
lines for the use and care of laboratory animals (National Research Council, 1996). The
experimental procedure was evaluated and approved by the Ethics Committee in Ani-
mal Research (CEPA) of the Federal University of Paraiba, Brazil.
Drugs and reagents
Carbamylcholine chloride (carbachol), oxytocin, histamine hydrochloride, acetyl-
choline chloride, arachidonic acid (AA), L-(–)-phenylephrine hydrochloride, (–)-scopo-
lamine hydrochloride and cremophor, macrogol glycerol ricinoleate, non-ionic polyetho-
xylated detergent were purchased from Sigma-Aldrich Co. All salts for the organ bath
solutions and reagents were purchased from Vetec (Rio de Janeiro, RJ, Brazil). Stock-
-solutions of all chemicals were prepared in distilled water. Compounds 5a, 6a, 11 and
12 were dissolved in cremophor. All stock-solutions were stored at –20 °C, and the dilu-
tions were made fresh on the day of the experiment.
Experimental procedures for the study of the spasmolytic activity of the compounds
were conducted similarly as described by Lima et al. (16) and are described below.
Tissue preparation and rat aorta and effects on the tonic contractions induced by phenyl-
ephrine. – Male Wistar rats (250–350 g) were killed by stunning and bleeding, their tho-
racic aorta was quickly removed and placed in Krebs’ solution with pH adjusted to 7.4
with 1 mol L–1 HCl, continuously bubbled with a gas mixture O2/CO2 (95:5, V/V). Fat
and connective tissues surrounding the aorta were removed, and the aorta was cut into
rings (3–4 mm length). Aortic rings were then suspended between two stainless steel
wires in an organ chamber containing 6 mL of Krebs’solution. One of the wires was an-
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chored in the organ chamber and the other was connected to a force-displacement trans-
ducer (Model 7003, UgoBasile, Italy). Isometric tensions of arterial tissues were recorded
on a polygraph.
Two submaximal tonic responses to phenylephrine (1 mmol L–1), which stabilized
in 12–15 minutes, were initially obtained. During the tonic phase of the third response to
phenylephrine, each of the test compounds (5a, 6a, 11 and 12) and scopolamine hydro-
chloride (positive control) were added individually in a concentration of 10–4 mol L–1,
and the contraction was measured again. The percentage of inhibition of the contraction
was calculated by comparing the response in the absence (100 %) and in the presence of
each tested compound and control.
Rat uterus and effecst on the phasic contractions induced by oxytocin
Virgin female Wistar rats (200–280 g) estrogenized with 1 mg kg–1 of estradiol ben-
zoate were used. The animals were killed by decapitation 24 h after injection and both
uterine horns were extracted and cleaned of adherences. Longitudinal strips, approxi-
mately 2–3 cm, were placed vertically in 6-mL isolated organ baths containing Locke
Ringer solution. In the same way, Locke Ringer solution was used without calcium and
was bubbled continuously with a gas mixture O2/CO2 (95:5, V/V) and maintained at 32 °C.
The pH was adjusted to 7.4 with 1 mol L–1 HCl. Each uterine horn was subjected to a
resting tension of 1 g and was allowed to equilibrate for at least 30–45 min before the
drugs were added to organ baths. Phasic contractions were recorded using isotonic lev-
ers coupled to kymographs and smoked drums (DTF, Brazil).
Strips from non-pregnant and estrogenized rat uterus were contracted with 10 mIU
ml–1 of oxytocin and after 10 min from washout a new contraction was elicited by the
agonist and the mean of the two contractions was considered as control (100 %). Before
the third contraction, each of the test compounds (5a, 6a, 11 and 12) and scopolamine
hydrochloride (positive control) were added individually to the organ bath, in a concen-
tration of 10–4 mol L–1, and the contraction was measured again after 10 min. Inhibition
was measured by comparing the response before and after addition of the agonist in the
presence of the test compound and control. The drugs were subsequently washed-out
and the recovery from contractions elicited by each drug and control was observed.
Guinea-pig ileum and effects on histamine-induced contractions. – To perform studies,
the guinea-pig ileum was prepared according to Daniel et al. (17). Guinea-pigs (300–500 g)
were killed by cervical dislocation, exsanguinated and the ileum was immediately re-
moved. Terminal portions, 3 cm long, were used after discarding the 10-cm portion close
to the ileocaecal junction. The tissues were placed vertically in 6 mL isolated organ baths
containing modified Krebs’ solution of the following composition (mmol L–1): NaCl
(117.0), KCl (4.7), CaCl2 (2.5), MgSO4 (1.3), NaH2PO4 (1.2), NaHCO3 (25.0), glucose
(11.0), bubbled with a gas mixture O2/CO2 (95:5, V/V) and maintained at 37 °C; pH was
adjusted to 7.4 with 1 mol L–1 HCl. Tension changes were recorded with an isometric
force transducer (Model 7003, UgoBasile) counter balanced by 1 g loading, connected to
a polygraph (Gemini 7070, UgoBasile). Phasic contractions were recorded using isotonic
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levers coupled to kymographs and smoked drums (DTF). The tissues were allowed to
stabilize for 30 min at a resting tension of 1 g. During the stabilization period, the modi-
fied Krebs solution was changed every 10 min to avoid accumulation of metabolites (18).
At the beginning of each experiment, the reactivity of tissue preparation was tested
with 40 mmol L–1 KCl. After washout and 15-min recovery in modified Krebs solution,
two submaximal tonic responses to histamine (1 mmol L–1), which stabilized in 12–15
minutes, were obtained initially. Compounds 5a, 6a, 11 and 12 and scopolamine hydro-
chloride (positive control), were added individually (10–4 mol L–1) after an incubation
period of 15 min; the third response to histamine (1 mmol L–1) was induced in the pre-
sence of the test compound and control. The tissue was washed when the agonist res-
ponse returned to the resting level. Inhibition was measured by comparing the response
before (100 %) and after addition of the test-compounds and control in the organ bath.
Guinea-pig trachea and effects on the contractions induced by carbachol. – Guinea-pigs of
both sexes (300–500 g), were killed by cervical dislocation, the abdomen was opened and
the trachea was quickly removed and dissected free of adhering fat and connective tis-
sue. From every trachea, four rings containing three to four cartilaginous segments were
obtained. Each tracheal ring was hung between two hooks inserted into the lumen, and
placed in a 6-mL organ bath containing Krebs’ solution maintained at pH 7.4, 37 °C, and
bubbled with a gas mixture O2/CO2 (95:5, V/V). Tracheal preparations were allowed to
stabilize for 60 min at a resting tension of 1 g basal tension. At the beginning of each
experiment, KCl 60 mmol L–1 was added once to evaluate the viability of the tissue. The
KCl contraction was taken into account for normalization of all subsequent responses to
the different agonists. After washout and 30 min recovery in Krebs solution, contractions
were evoked by adding carbachol (10–6 mol L–1). The integrity of the functional epithe-
lium was verified by the addition of arachidonic acid (AA) to the organ bath in the con-
centration of 10–4 mol L–1 (19). During the tonic phase of the first contractile response
induced by 10–6 mol L–1 carbachol, tracheal rings that showed superior relaxations to 50 %
(in relation to the force of initial contraction) were considered with epithelium. Isometric
contractions were measured with a force transducer (World Precision Instruments, Model
FORT-10, USA) coupled to an amplifier (World Precision Instruments, Model TMB4M,
USA), connected to a A/D converter into a PC running Biomed® software v.Rv2 (BioData,
Ribeirao Preto, Brazil).
After the resting period, the tracheal rings were contracted with carbachol (10–6 mol
L–1) and the isometric tension was recorded. In second carbachol-induced stable contrac-
tion, compounds 5a, 6a, 11 and 12 and scopolamine hydrochloride (positive control, 10–5
mol L–1) were added individually to the organ bath. The inhibition was measured by
comparing the response before and after addition of the agonist in the presence of the
test compounds and scopolamine in the organ bath.
Statistical analysis
All data were statistically analyzed using Student’s t-test and the differences were
considered significant when p < 0.05.
237
J. A. S. Luis et al.: Synthesis and preliminary ex vivo evaluation of the spasmolytic activity of 1,3-thiazolium- and 1,3,4-thiadiazolium-
5-methylthio- and 5-thioacetate derivatives, Acta Pharm. 64 (2014) 233–245.
RESULTS AND DISCUSSION
Chemistry
Two classes of compounds were obtained in this work, the 1,3-thiazolium-5-thiolate
and the 1,3,4-thiadiazolium-5-thiolate derivatives. 1,3-Thiazolium-5-thiolate derivatives
were obtained through a synthetic pathway started by a Strecker reaction of benzalde-
hyde derivatives (1a–c) with sodium cyanide and affording C-aryl-N-methyl-glycines
(2a–c). These were aroylated to give C-aryl-N-aroyl-N-methyl-glycines (3a–d). The me-
soionics 4a–d were obtained via cyclodehydratation to non-isolated 1,3-oxazolium-5-
-olates, followed by a 1,3-dipolar cycloaddition and cycloreversion sequence induced by
CS2, and elimination of CO2 (14) (Scheme 1).
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5a: R = Cl; R = H1 2
5b: R = Cl; R = CH(CH )1 2 3 2
5c: R = Cl; R = OCH1 2 3
6a: R = Cl; R = H1 2



































































The synthesis of the 1,3,4-thiadiazolium-5-thiolate mesoionics (10a,b) started
through the reaction of phenylhydrazine (7) with CS2 and KOH to give potassium
b -phenyl-carbazoate (8). This was aroylated with benzoyl chloride and 4-chlorobenzoyl
chloride (9a,b) affording the mesoionic system (10a,b) (15) (Scheme 2).
The last reaction step was conversion of the two mesoionic systems (4a–d and 10a,b)
into their respective salts, through their treatment with chloroacetic acid or methyl iod-
ide. This procedure gave the new seven compounds derived from mesoionics 5a–c, 6a,b,
11 and 12, which were characterized based on their physical, analytical and spectral data,
which were in full agreement with the proposed structures (Tables I, II).
According to a previous work (14), assignments of the mesoionic ring carbon atoms
C-3, C-4 and C-5 of the 1,3-thiazolium-5-thiolate system, and C-2 and C-5 of the 1,3,4-
-thiadiazolium-5-thiolate ring are of special importance for unequivocal structural elu-
cidation. Chemical shifts of these carbon atoms are influenced by shielding in the HOMO
region and deshielding in the LUMO region.
For compounds 5a–c, C-4, C-2 and C-5 were the most deshielding carbon atoms.
Assignments of C-4 at d 139.9, 149.9 and 148.9 ppm to 5a, 5b and 5c, respectively, are
considered to be due to shielding when compared to C-5 at d 167.9, 168.0 and 167.2 ppm,
respectively. As described by Lira et al. (14), electron delocalization in the HOMO region
restricts negative p-charge to C-4. Chemical shifts at d 149.3, 152.6 and 161.4 ppm (5a, 5b
and 5c, respectively) were attributed to C-2, and were influenced by deshielding in the
LUMO region in which positive p-charge is delocalized.
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The 1H NMR of 5a–c had two intense and characteristics singlets integrating for 3H
corresponding to the N-methyl and S-methyl groups. These singlets appeared at d 3.81
(N-Me) and 2.49 ppm (S-Me) for 5a, at d 3.84 (N-Me) and 2.50 ppm (S-Me) for 5b, and at
d 3.73 (N-Me) and 2.40 ppm (S-Me) for 5c. For 5c, an additional singlet, integrating for
3H at d 3.75 ppm, corresponds to the O-methyl group.
For the 5-thioacetate derivatives (6a and 6b), the signals in the 13C NMR at d 141.3,
152.9 and 171.8 ppm (for 6a) and at d 141.6, 153.0 and 169.8 ppm (for 6b) were associated
with carbons C-4, C-2 and C-5, respectively. Signals at d 39.3 and 41.0 ppm were attri-
buted to the carbons of the methylene groups (C-15), and those at d 41.6 and 40.7 ppm to
the carbons of the N-methyl group (C-10). The most deshielding signals, appearing at d
172.0 and 173.9 ppm, were assigned to the carbons of the carboxylate group (COO–). The
1H NMR spectra of 6a and 6b, present two intense singlets, one of them integrating for
3H at d 3.79 (for 6a) and 3.46 ppm (for 6b) corresponding to N-methyl hydrogens, and
the other integrating for 2H at d 3.75 (for 6a) and 3.67 ppm (for 6b), corresponding to the
methylene group (S-CH2-COO–).
For 5b and 6b, septets at d 2.97 (5b) and 2.89 ppm (6b) integrating for 1H and a
doublet integrating for 6H at d 1.27 (5b) and 1.23 ppm (6b) indicate the presence of the
isopropyl residues.
13C NMR data of 1,3,4-thiadiazolium derivatives shows signals at d 168.2 and 169.5
ppm (for 12), and at d 173.2 and 173.5 ppm (for 11) attributed, respectively, to the carbons
C-2 and C-5. Chemical shifts 13C at d 17.4 (for 11), and at d 35.8 and 173.2 ppm (for 12)
demonstrate unequivocally the presence of the 5-methylthio and 5-thioacetate groups in
these molecules. The 1H NMR data confirms these attributions show for 11 the presence
of one singlet, integrating for 3H, at d 2.90 ppm, and for 12, one singlet, integrating for
2H, at d 3.97 ppm.
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2.49 (s, 3H, H-15), 3.81 (s, 3H,
H-10), 7.52 (m, 5H, H-12, 12’,13,13’
and 14), 7.88 (d, 2H, H-7 and 7’, J =
8.2 Hz), 8.09 (d, 2H, H-8 and 8’, J =
8.2 Hz)
20.7 (C-15), 41.4 (C-10), 123.3 (C-11),
126.5 (C-9), 129.2 (C-14), 129.9 (C-13
and 13’), 131.1 (C-12 and 12’), 131.3
(C-7 and 7’), 132.4 (C-8 and 8’), 135.3







1.27 (d, 6H, CH(CH3)2, J = 7.0 Hz),
2.97 (sept, 1H, CH(CH3)2, J = 6.2
Hz), 2.50 (s, 3H, H-15), 3.84 (s, 3H,
H-10), 7.39 (d, 2H, H-13 and 13’, J =
8.4 Hz), 7.56 (d, 2H, H-8 and 8’, J =
7.8 Hz), 7.79 (d, 2H, H-12 and 12’, J
= 8.4 Hz), 8.08 (d, 2H, H-7 and 7’, J
= 7.8 Hz)
20.7 (C-15), 23.7 (CH(CH3)2), 34.1
(CH(CH3)2), 41.4 (C-10), 123.8 (C-11),
140.1 (C-9), 123.5 (C-14), 127.5 (C-13
and 13’), 130.0 (C-12 and 12’), 131.1
(C-7 and 7’), 132.4 (C-8 and 8’), 135.2








2.40 (s, 3H, H-15), 3.73 (s, 3H,
H-10), 3.75 (s, 3H, O-CH3), 6.91 (d,
2H, H-13 e 13’, J = 8.2 Hz), 7.42 (d,
2H, H-8 and 8’, J = 7.8 Hz), 7.73 (d,
2H, H-12 and 12’, J = 8.2 Hz), 8.04
(d, 2H, H-7 and 7’, J = 7.8 Hz)
20.2 (C-15), 41.2 (C-10), 55.2 (O-CH3),
114.4 (C-13 e 13’), 118.2 (C-14), 123.3
(C-11), 129.5 (C-12 and 12’), 139.4
(C-9), 132.2 (C-7 and 7’), 132.5 (C-8





3.75 (s, 2H, H-15), 3.79 (s, 3H,
H-10), 7.64–7.90 (m, 9H, ArH)
39.3 (C-15), 41.6 (C-10), 125.3 (C-7
and 7’), 128.4 (C-11), 130.6 (C-8 and
8’), 131.3 (C-12 and 12’), 131.7 (C-14),
132.7 (C-13 and 13’), 132.9 (C-6),
133.8 (C-9), 141.3 (C-4), 152.9 (C-2),






1.23 (d, 6H, CH(CH3)2, J = 7.2 Hz),
2.89 (sept, 1H, CH(CH3)2, J = 6.4
Hz), 3.46 (s, 3H, H-10), 3.67 (s, 2H,
H-15), 7.29 (d, 2H, H-13 and 13’, J =
8.0 Hz), 7.44 (d, 2H, H-8 and 8’, J =
7.6 Hz), 7.83 (d, 2H, H-12 and 12’, J
= 8.0 Hz); 8.16 (d, 2H, H-7 e 7’, J =
7.6 Hz)
23.4 (CH(CH3)2), 34.0 (CH(CH3)2),
40.7 (C-10), 41.0 (C-15), 120.8 (CF3),
125.2 (C-8 and 8’), 126.3 (C-13 and
13’), 126.8 (C-12 and 12’), 127.7 (C-7
and 7’), 129.5 (C-11), 130.2 (C-9),
133.6 (C-6), 141.6 (C-4), 151.64 (C-14),




3.97 (s, 2H, H-14),
7.22–7.40 (m, 10H, ArH)
35.8 (C-14), 121.8 (C-6), 125.3 (C-12
and 12’), 129.8 (C-8 and 8’), 129.9
(C-11 and 11’), 130.0 (C-13), 131.9
(C-9), 134.4 (C-7 and 7’), 136.6 (C-10),
168.2 (C-5), 169.6 (C-2), 173.2 (C-15)
12a 3056, 1715,
1600, 1490
2.90 (s, 3H, H-14),
7.55–7.75 (m, 9H, ArH)
17.4 (C-14), 122.4 (C-6), 127.3 (C-12
and 12’), 130.9 (C-13), 131.1 (C-11
and 11’), 133.1 (C-7 and 7’), 133.3
(C-8 and 8’), 138.5 (C-10), 141.7 (C-9),
173.2 (C-5), 173.5 (C-2)
Multiplicities were indicated as follows: s (singlet); d (doublet); t (triplet), sept (septet) and m (multiplet).
a CDCl3; b CD3OD.
The main vibrational bands of the title compounds are given in Table II. IR spectra
showed absorption bands for all compounds at about 3079–2872 cm–1 characteristic of
C-HAr and C-HAliph stretching vibrations, and at about 1612–1433 cm–1, characteristic of
C=C and C=N mesoionic ring stretching. Compounds 6a, 6b and 12 showed further in-
tense characteristic absorption bands at 1719, 1712 and 1715 cm–1, respectively, due to
axial carbonyl deformation (C=O).
Spasmolytic activity
Compounds 5a, 6a, 11 and 12 were selected and evaluated for their spasmolytic acti-
vity on smooth muscle isolated from rats and guinea pigs and compared to scopolam-
ine. The results are summarized in Table III.
The data presented in Table III show that all tested compounds were able to induce
relaxation on muscles isolated from rats and guinea pigs in the presence of their
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Table III. Spasmolytic activity of compounds 5a, 6a, 11 and 12 and scopolamine in smooth muscles
induced by phenylephrine, carbachol, oxytocin and histamine
Compound Tissue Agonist Inhibition (%)a Concentration (mol L–1)
5a Aorta Phenylephrine 55.5 ± 1.2b 10–4
Trachea Carbachol 97.2 ± 1.6b 10–5
Uterus Oxytocin 98.3 ± 1.2b 10–4
Ileum Histamine 45.3 ± 1.4b 10–4
6a Aorta Phenylephrine 55.5 ± 1.2c 10–4
Trachea Carbachol 97.2 ± 1.6c 10–5
Uterus Oxytocin 98.3 ± 1.2c 10–4
Ileum Histamine 45.3 ± 1.4c 10–4
11 Aorta Phenylephrine 72.5 ± 2.8b,c,d 10–4
Trachea Carbachol 83.3 ± 1.9b,c,d 10–5
Uterus Oxytocin 80.5 ± 1.6b,c,d 10–4
Ileum Histamine 22.9 ± 1.4b,c,d 10–4
12 Aorta Phenylephrine 78.7 ± 2.1b,c,d,e 10–4
Trachea Carbachol 90.5 ± 1.9b,c,d 10–5
Uterus Oxytocin 94.3 ± 1.6b,c,d 10–4
Ileum Histamine 34.7 ± 2.4b,c,d,e 10–4
Scopolamine Aorta Phenylephrine 82.5 ± 1.2b,c,d,e 10–4
Trachea Carbachol 92.3 ± 1.4b,c,d 10–5
Uterus Oxytocin 94.3 ± 1.2b,c,d 10–4
Ileum Histamine 60.8 ± 1.6b,c,d,e 10–4
a Mean value ± SD of five tests, p < 0.05.
Significant differences (p < 0.05) for respective muscles were observed: b,c 5a and 5b vs. 11, 12, scopolamine;
d 11 vs. 12, scopolamine, for all muscles; e 12 vs. scopolamine for aorta and ileum.
respective agonists. The compounds inhibited more efficiently the contractions in the
uterus and trachea (80–98 %), the ileum being the muscle with lower spasmolytic res-
ponse (23–45 %). Similar results were obtained with the reference drug scopolamine
which was able to inhibit the contractions of the uterus and trachea by 92 and 94 %, res-
pectively (higher response), and ileum by 60 % (lower response).
Compounds 5a and 6a had the same percentage of inhibition of contractions for all
tested muscles, demonstrating no or very little importance of the thioacetate and me-
thylthio groups linked to C-5 for the spasmolytic activity in the case of 1,3-thiazolium
derivatives.
For compounds having the 3,4-thiadiazolium system (11 and 12) the presence of the
5-thioacetate group (in 12) proved to be important for increasing the activity, promoting
an increase in contraction inhibition in all smooth muscles evaluated, reaching a maxi-
mum increase of 50 % for ileum. Among tested compounds, compound 11 was the least
active for three of the four muscles evaluated (trachea, uterus and ileum). However, it
exerted higher spasmolytic activity on rat aorta (72 vs. 55 %) than both 1,3-thiazolium
derivatives (5a and 6a).
This means that in three of among the four tested muscles (ileum, trachea and uter-
us), 1,3-thiazolium derivatives (5a, 6a) had superior inhibitory activity over 1,3,4-thia-
diazolium derivatives (11, 12). The aorta was the only exception where 11 and 12 show-
ed inhibition greater than 70 % of, whereas compounds 5a and 6a were able to inhibit
contractions by only 55 %.
CONCLUSIONS
All compounds undergoing pharmacological screening in smooth muscle showed
good activities in muscles isolated from rats and guinea pigs (aorta, uterus, ileum and
trachea). Compounds 5a, 6a and 12 exhibited a depressant activity equal to or greater
than scopolamine in uterus and trachea, indicating that mesoionic derivatives could be
promising compounds for the development of new spasmolytic agents. However, fur-
ther investigation is currently under way in our laboratory in order to determine the
IC50, toxicity, to check the reversibility of the effect and elucidate the mode of action at
the molecular level.
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